Ko Ko, Akita Tomoyuki, Satake Masahiro, Tanaka Junko
Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
Glob Health Med. 2021 Oct 31;3(5):262-269. doi: 10.35772/ghm.2021.01069.
Although HCV infection was the main cause of HCC in Japan contributing 70% over two decades after its first cloning in 1989, it was markedly decreased to 49% in 2013 and expected to decrease continuously. Based on blood donor national database, the new incident cases were 0.4/100,000 person-years, the prevalence was 0.13% and the total number was 890,902-1,302,179 in 2015. Establishment of blood donor screening with anti-HCV measurement and nucleic acid test introduced by Japanese Red Cross as pioneer, high-level medical and surgical care, and the government's policy under the Basic Act on Hepatitis Control have changed its epidemiology and outbreak trend and also enforced the disruption of potential transmission cascades. HCV prevalence among the younger generation was extremely low in all regions, and the predominant age for HCC has shifted to over 60 years old population. Considering such changes, HCV induced HCC occurrence is supposed to be ultimately suppressed in the near future. However, taking into account society changes, regulating intravenous drugs users and monitoring high-risk groups such as tattoos, and men who have sex with men are indeed required in Japan. Understanding the epidemiological changes in HCV is important in assigning, modifying, and designating effective response systems. Selective or national action plans, strategic approaches, and cooperation between government sectors have a positive impact on HCV prevention and control. A dramatic decrease in total number of HCV carriers, increase in number of people treated with highly effective DAA, and subsequent high SVR indicates Japan might achieve WHO's target of HCV elimination by 2030.
尽管丙型肝炎病毒(HCV)感染是日本肝细胞癌(HCC)的主要病因,在1989年首次克隆该病毒后的二十多年里,其导致的HCC占比达70%,但在2013年这一比例显著降至49%,且预计还会持续下降。根据全国献血者数据库,2015年新发病例为每10万人年0.4例,患病率为0.13%,总数为890,902 - 1,302,179例。日本红十字会率先开展了抗HCV检测和核酸检测的献血者筛查,高水平的医疗和外科护理,以及政府依据《肝炎防治基本法》制定的政策,改变了其流行病学和发病趋势,也阻断了潜在的传播链。所有地区年轻一代中的HCV患病率极低,HCC的主要发病年龄已转向60岁以上人群。考虑到这些变化,预计在不久的将来,HCV导致的HCC发生最终会得到抑制。然而,考虑到社会变化,在日本确实需要对静脉吸毒者进行管控,并对纹身者和男男性行为者等高风险群体进行监测。了解HCV的流行病学变化对于制定、调整和指定有效的应对系统至关重要。选择性或全国性的行动计划、战略方法以及政府部门之间的合作对HCV的预防和控制具有积极影响。HCV携带者总数的大幅下降、接受高效直接抗病毒药物(DAA)治疗人数的增加以及随后的高持续病毒学应答率表明,日本可能实现世界卫生组织(WHO)在2030年消除HCV的目标。